[ad_1] Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO Accessibility Statement Skip Navigation […]
Tag: Ltd
Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM
[ad_1] Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM Accessibility Statement Skip Navigation In the OptiTROP-Lung04 […]
United Imaging Marks Five Years Since the Opening of its Global Showroom In North America with a Record Number of U.S. Customer Visits
[ad_1] The company launched American R&D in 2013 and American commercial operations in 2018; in 2020 it opened a 100,000 square foot production and training center in Houston, and just tripled its local footprint to […]
Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO
[ad_1] Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO Accessibility Statement Skip Navigation In the OptiTROP-Breast02 study, a total of 399 patients […]
Kelun-Biotech’s Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC
[ad_1] CHENGDU, China, Oct. 17, 2025 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”) announced that the Company’s human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate (ADC) trastuzumab botidotin (also known as A166) was approved for marketing by the […]
